Exchange: NASDAQ·Updated 04:10 PM EST

MOLN News

News
all
press releases
After Plunging 18.3% in 4 Weeks, Here's Why the Trend Might Reverse for Molecular Partners AG Sponsored ADR (MOLN)
The heavy selling pressure might have exhausted for Molecular Partners AG Sponsored ADR (MOLN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks
After Plunging 18.3% in 4 Weeks, Here's Why the Trend Might Reverse for Molecular Partners AG Sponsored ADR (MOLN)
The heavy selling pressure might have exhausted for Molecular Partners AG Sponsored ADR (MOLN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks
More News
Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Get Free Report) was the target of a large drop in short interest in April. As of April 15th, there was short interest totaling 12,887 shares, a...
MarketBeat
HC Wainwright reaffirmed a "buy" rating and issued a $13.00 price target on shares of Molecular Partners in a report on Wednesday...
MarketBeat
Molecular Partners (NASDAQ:MOLN) Trading Up 5% - Time to Buy...
MarketBeat
Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Get Free Report) was the recipient of a large decrease in short interest during the month of March. As of March 13th, there was short interest...
MarketBeat
Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Free Report) - Equities research analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for Molecular Partners in a...
MarketBeat
HC Wainwright reaffirmed a "buy" rating and set a $13.00 price objective on shares of Molecular Partners in a research note on Monday...
MarketBeat
Molecular Partners (NASDAQ:MOLN - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus...
MarketBeat
PBR gears up for fourth-quarter results as pre-salt output hits 3,109 MBOE/d, but refining outages and weaker fuel production may weigh on margins.
Zacks
Molecular Partners (NASDAQ:MOLN) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 5. (View Earnings Report at...
MarketBeat

Advertisement|Remove ads.